Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
NCT ID: NCT01016782
Last Updated: 2014-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
867 participants
INTERVENTIONAL
2008-01-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment medication will be administered as follows: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
NCT02393937
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01174030
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
NCT02547441
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01318733
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
NCT01513863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test
Test product that contains active pharmaceutical ingredient
0444
A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Reference
Reference product that contains active pharmaceutical ingredient
0444
A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Vehicle
Placebo that contains no active pharmaceutical ingredient
0444
A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0444
A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good health with the exception of rosacea
* Papsules and pustules minimum and maximum requirements
Exclusion Criteria
* Subjects who have any systemic or dermatological disorders with the exception of rosacea
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fougera Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angela C Kaplan
Role: STUDY_DIRECTOR
Fougera Pharmaceuticals Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0444
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.